Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Disease
- Cancer
- Therapeutic
- HIV / AIDs
- Immune
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 248598
Licensor grants an exclusive license, under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used and to sell and have sold any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
The technology for Oncology will include the performance of Phase I – Phase IV. For AIDS it includes Preliminary investigative research to establish an in vitro model for the efficacy of either phenylacetate or phenylbutyrate for inhibiting the replication of the AIDS virus. And for anemia, that phenylacetate and phenylbutyrate stimulate HbF production in cultured erythroid progenitor derived from normal donors and patients with sickle cell anemia or B-thalassemia.
Licensed Patent Rights shall mean U.S. Patent Application 07/779,744 and, 08/135,661, and, 08/207,601.
Licensed Fields of Use All fields of use identified in U.S. Patent Application Serial Nos. 07/779,744, 08/135,661 and 08/207,601, including but not limited to, the following
1) therapy and prevention of cancer
2) therapy and prevention of anemia
3) therapy and prevention of AIDS
IPSCIO Record ID: 248319
Sodium Phenylbutyrate, or PB, is a small molecule that was previously approved by the FDA for sale as a treatment for a rare genetic disorder in infants known as hyperuremia. PB has a number of additional mechanisms of action, including the inhibition of histone deacetylase. Histone deacetylase is a class of enzymes that remove acetyl groups from the amino acids in DNA. The inhibition of histone deacetylase allows the body’s cancer suppressing genes to work as intended. In addition, PB is not toxic to cells. These characteristics make PB a good candidate to become a chemopotentiator. A chemopotentiator is a substance that enhances the activity of a chemotherapeutic agent. As a result, PB is designed to be administered in conjunction with radiation and chemotherapy.
Licensed Fields of Use All fields of use identified in U.S. Patent Application Serial Nos.
07/779,744, 08/135,661 and 08/207,601, including but not limited to, the following
1) therapy and prevention of cancer
2) therapy and prevention of anemia
3) therapy and prevention of AIDS
IPSCIO Record ID: 230824
(a) under all of Licensors rights in the Pre-Existing Oncology Inventions, to make, have made, use, offer for sale, sell, and import any products and practice any methods related to the Pre-Existing Oncology Inventions; and
(b) under all of Licensors rights in the Pre-Existing Oncology Technology, the right to reproduce, distribute, prepare derivative works of, publicly perform and publicly display any Pre-Existing Oncology Technology. The foregoing licenses will be exclusive, even as to Licensor.
For the Ownership of Sponsored Research Inventions and Technology, Licensee will own all right, title and interest in the Sponsored Research Inventions and Sponsored Research Technology. The Licensor transfers and assigns to Licensee and shall assign to Licensee all right, title and interest in and to the Sponsored Research Technology and Sponsored Research Inventions and all intellectual property rights therein.
For the Exclusive License to Licensor Oncology Inventions and Licensor Oncology Technology. The Licensor grants to Licensee an irrevocable, sublicenseable right
(a) to make, have made, use, offer for sale, sell, and import any products and practice any methods related to the Licensor Oncology Inventions; and
(b) to reproduce, distribute, prepare derivative works of, publicly perform and publicly display any Licensor Oncology Technology.
Oncology and Supportive Care Applications means the field of oncology, including research, development, and commercialization of products and services for the treatment or diagnosis of all cancers, including carcinomas and sarcomas, and neoplastic conditions; and supportive care applications, which includes without limitation care of manifestations of cancer, prevention and treatment of complications and side-effects of treatment and therapy, management of cancer, and palliative care.
IPSCIO Record ID: 3470
Technical Information shall mean information related to therapies and treatments for sickle cell disease and thalassemia that provide a commercial advantage.
Patent refers to rights under United States Patent No. 5,693,671, together with any reissue or reexamination that may issue therefrom.
The Licensee may sublicense.
IPSCIO Record ID: 230759
A Licensed Process is any process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights; or, Patent Rights; or, is derived from Patent Rights or know-how, and related to or described in is sold, manufactured or used in any country under this Agreement.
A Licensed Product shall mean any product or part thereof which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Products are made, used or sold; or, is manufactured by using a process which is covered in whole or in part by an issued, unexpired claim or a pending claim contained in the Patent Rights in the country in which any Licensed Process is used or in which such product or part thereof is used or sold; or,
is derived from Patent Rights or know-how, and related to or described in Patent Rights.
(a) Human [blood] disorders, [metabolic and congenital]. This field includes human [hematological] diseases that arise due to the absence, over-expression or altered expression of proteins normally (present in blood]. The primary site and location of these proteins is [blood]. Specifically included are human [hemoglobinopathies (i. e. Sickle Cell Anemia and Thalassemia)] and human disorders of the [coagulation metabolism (i.e., Hemophilia A (factor VIII), Von Willebrands Disease (factor VIII) and Hemophilia B (factor IX))]. Specifically excluded are human [neoplasias of the lymphoreticular system (lymphomas, reticuloendothelioses, or plasma cell dyscrasias)].
(b) Human [malignant neoplastic] diseases. This field includes all forms of human (cancer, including but not limited to skin cancers and all solid tumors]. This field also includes all forms of human [cancers of the hematopoietic tissues (the leukemias), Hodgkins Disease and Non-Hodgkins Lymphoma].
c) relating to a syndrome (AIDS) characterized by opportunistic infections occuring as a result of profound
deficiency of the helper – T4 lymphocytes (CD4 lymphocytes). At any time during the life of this Agreement the definition of AIDs shall be that definition currently in use by the Centers for Disease Control, Atlanta, Georgia].
(d) All human [infectious diseases other than HIV]. This Field includes [human viral diseases (besides HIVs, human bacterial, yeast and other microorganism based diseases, and all other human infectious diseases.
